I have worked in clinical pathology for more than 20 years. After my specialist examination at Humboldt University in Berlin, Germany, I started to dedicate in breast pathology in 2004 at Oskar-Ziethen Hospital in Berlin, one of Germanys breast centers. 2005-2015 I worked in Växjö as a senior consultant and responsible breast pathologist. Since 2015, I have been working as a senior consultant in the Institute of Clinical Pathology at Kalmar Country Hospital, as one of three breast pathologists. Simultaneously with the new employment in Kalmar, I started a research project at the University in Lund, focusing on breast carcinoma. I am particularly interested in tumor infiltrating lymphocytes (TILs). My research is based on a large prospective cohort study established in southern Sweden in 1990. In this study, 1500 breast carcinoma cases have occurred, which I have reviewed and classified according to current international standards within five years. In my clinical work, I spend more than 50% of my working time on breast diagnostics and diagnose more than 50 new breast carcinoma cases per year. Hereby I fulfill the requirements of the European Society of Breast Cancer Specialists (EUSOMA) as breast pathologist. I constantly keep up to date by attending national and international meetings and congresses as well as studying the literature.
Clinical Pathology in Kalmar seems to be the first pathology in the world to use digitized histopathological sections in routine diagnostics since 2008. Today, all histopathology sections in Kalmar are scanned. As the pathologist responsible for digital pathology in the institute, I am constantly driving the development.
Since the fall of 2021, I have been part of the Sweden-wide project Swedish AI Precision Pathology (SwAIPP) to contribute with my experience as a longtime breast pathologist to develop an artificial intelligence (AI)-based tool for breast diagnostics.
With my approximately 30 years of experience as a hobby photographer in combination with my experience as a pathologist and first-class equipment for taking histology and cytology images, there are best requirements to getting high-quality histology and cytology images, for example for scientific publications.
With this background, I am the right partner for you if you need help in your breast cancer research, development of AI-based solutions in breast cancer diagnostics or in creating high quality histology and cytology images.
I look forward to getting in touch with you!
Important points in my CV
|1997||Dissertation in Pathology, Humboldt-University Berlin, Germany|
|2010-2014||Medical chief, Institute for Clinical pathology/cytologi, Country hospital in Växjö, Sweden|
|2014-2019||Board member, Swedish Society of Pathology|
|2015||Examiner Mid-term review of doctoral thesis by Björn Isfoss "Histopathological characterization of stem cells for the mammary epithelium and stroma", supervisor Håkan Olsson, Lund University, Sweden|
|2020||English research writing, 6 month at Linné University in Växjö, Sweden|
|1999-||Participated in a number of symposia, also as a lecturer|
|1990-||Special interest photography: www.utesbilder.se|
Michailidou, K.-et al. Association analysis identifies 65 new breast cancer risk loci. Nature. 2017 Nov 2;551(7678):92-94. doi: 10.1038/nature24284.
Co-author in chapter „Hemangioma of the breast“ to the Encyclopedia of Pathology, edited by Han van Krieken, Springer, 2018 Jun 20:e DOI: https://doi.org/10.1007/978-3-319-28845-1_4753-1
Mavaddat, N et al. Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. Am J Hum Genet 2019;104(1):21-34.
Johnsson, A et al. Post-diagnosis physical activity and survival after diagnosis of breast cancer. Eur J Cancer Care. 2019 Mar 21:e13037. doi: 10.1111/ecc.13037.
Genome-wide association study of germline variants and breast cancer-specific mortality.
Escala-Garcia, M et al. Br J Cancer. 2019 Mar;120(6):647-657. doi
Lundgren, C et al. Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up. Breast Cancer Res. 2020 Dec 23;22(1):140. doi: 10.1186/s13058-020-01364-w.
Middha P. et al. Gene-environment interactions and breast cancer risk. Int J Epidemiol (submitted)
Ahearn, T et al. Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research. (submitted)
Ute K, Hubert M, Elisabet E (2022) Guillain-Barré Syndrome and vasculitis-like changes following severe acute respiratory syndrome coronavirus 2 Vaccination, chemotherapy, and Rituximab. J Med Case Rep Case Series 3(14): https://doi.org/10.38207/JMCRCS/2022/DECB20031401104